


## WE CLAIM:

1. A compound having the structure of Formula I:



and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs, metabolites, wherein

$R_1$  and  $R_2$  are independently selected from  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_7$  cycloalkenyl or optionally substituted phenyl wherein optional substituent(s) is/are selected from  $C_1$ - $C_3$  alkyl,  $C_1$ - $C_3$  alkoxy or halogen;

$R_3$  represents  $C_1$ - $C_6$  alkyl wherein 1-3 hydrogen atom(s) may be replaced by  $C_5$ - $C_7$  cycloalkyl, 1, 3-dioxo-1, 3-dihydro-isoindolyl or optionally substituted phenyl wherein the optional substituent is/are selected from  $C_1$ - $C_4$  alkyl or halogen;

Z represents oxygen or  $NR_4$  wherein  $R_4$  represents hydrogen or  $C_1$ - $C_3$  alkyl.

2. A compound selected from:

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-{[4-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-butyl]-3-azabicyclo[3.1.0]hex-6-yl-methyl}-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 1)

(2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopent-1-enyl-2-phenylacetamide (Compound No. 2)

(2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Isopropyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 3)


- 9 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Diphenylmethyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-  
10 2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 4)
- 11 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-sec-butyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
12 hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 5)
- 13 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
14 hydroxy-2-(3-pentyl)-2-phenylacetamide (Compound No. 6)
- 15 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
16 hydroxy-2-cyclohexyl-2-(4-methoxyphenyl) acetamide (Compound No. 7)
- 17 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
18 hydroxy-2-phenyl-(N-ethyl)-2-phenylacetamide (Compound No. 8)
- 19 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
20 hydroxy-2-cyclopentyl-(N-ethyl)-2-phenylacetamide (Compound No. 9)
- 21 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
22 hydroxy-2-cyclohexyl-(N-ethyl)-2-phenylacetamide (Compound No. 10)
- 23 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)- 2-  
24 hydroxy-2-(3-pentyl)-(N-methyl)-2-phenylacetamide (Compound No. 11)
- 25 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
26 hydroxy-2-(sec-butyl)-(N-methyl)-2-phenylacetamide (Compound No. 12)
- 27 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
28 hydroxy-2-isopropyl-(N-methyl)-2-phenylacetamide (Compound No. 13)
- 29 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-tert-butyl-benzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
30 methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 14)
- 31 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
32 hydroxy-2-cyclohex-2-enyl-2-phenylacetamide (Compound No. 15)
- 33 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
34 methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 16)

- 35 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
36 methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 17)
- 37 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(4-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
38 methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 18)
- 39 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
40 methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 19)
- 41 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-  
42 2-hydroxy-2,2-diphenylacetamide (Compound No. 20)
- 43 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(3-fluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-methyl]-  
44 2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 21)
- 45 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[2-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
46 methyl]-2-hydroxy-2-cyclohexyl-2-phenylacetamide (Compound No. 22)
- 47 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(2,4-difluorobenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
48 methyl]-2-hydroxy-2,2-diphenylacetamide (Compound No. 23)
- 49 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-[3-(3-methylbenzyl)-3-azabicyclo[3.1.0]hex-6-yl-  
50 methyl]-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 24)
- 51 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
52 hydroxy-2-(4-methylphenyl)-2-phenylacetamide (Compound No. 25)
- 53 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
54 hydroxy-2-(4-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 26)
- 55 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
56 hydroxy-2-(4-fluorophenyl)-2-phenylacetamide (Compound No. 27)
- 57 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
58 2-(4-fluorophenyl)-2-phenyl acetic acid ester (Compound No. 28)
- 59 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
60 hydroxy-2-(4-fluorophenyl)-(N-methyl)-2-phenylacetamide (Compound No. 29)

- 61 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
62 hydroxy-2-(3-methylphenyl)-2-phenylacetamide (Compound No. 30)
- 63 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
64 hydroxy-2-(3-methylphenyl)-(N-methyl)-2-phenylacetamide (Compound No. 31)
- 65 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
66 2-(3-methylphenyl)-2-phenyl acetic acid ester (Compound No. 32)
- 67 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
68 2-cyclopentyl-2-(3-methylphenyl) acetic acid ester (Compound No. 33)
- 69 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
70 2-cyclopentyl-2-(3-methylphenyl) acetic acid ester tartarate salt (Compound No.  
71 34)
- 72 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
73 hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide (Compound No. 35)
- 74 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
75 hydroxy-2-cyclopentyl-2-(3-methylphenyl) acetamide tartarate salt (Compound  
76 No. 36)
- 77 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
78 hydroxy-2,2-di(4-fluorophenyl)acetic acid ester (Compound No. 37)
- 79 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
80 hydroxy-2,2-di(4-fluorophenyl)-acetamide (Compound No. 38)
- 81 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
82 2-cyclobutyl-2-phenyl acetic acid ester (Compound No. 39)
- 83 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-cyclohexylmethyl-3-azabicyclo[3.1.0]hex-6-yl-  
84 methyl)-2-hydroxy-2-cyclopentyl-2-phenylacetamide (Compound No. 40)
- 85 (2R) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-2-  
86 cyclopentyl-(N-methyl)-2-phenylacetamide (Compound No. 41)

- 87 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-  
88 hydroxy-2-cyclopentyl-2-(4-methylphenyl) acetamide (Compound No. 42)
- 89 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
90 2-phenyl-2-(4-methylphenyl) acetic acid ester (Compound No. 43)
- 91 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
92 2-methyl-2-phenyl acetic acid ester (Compound No. 44)
- 93 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-  
94 hydroxy-2-methyl-2-phenyl acetamide (Compound No. 45)
- 95 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
96 2-isopropyl-2-phenyl acetic acid ester (Compound No. 46)
- 97 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-methyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-  
98 hydroxy-2-phenyl-(N-methyl)-2-phenylacetamide (Compound No. 47)
- 99 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl]-2-  
100 hydroxy-2-(3-methylphenyl)-2-(3-methylphenyl) acetamide (Compound No. 48)
- 101 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-hydroxy-  
102 2-(3-pentyl)-2-phenyl acetic acid ester (Compound No. 49)
- 103 (2R, 2S) (1 $\alpha$ , 5 $\alpha$ , 6 $\alpha$ )-N-(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl-methyl)-2-  
104 hydroxy-2-methyl-(N-methyl)-2-phenylacetamide (Compound No. 50)
- 1 3. A pharmaceutical composition comprising a therapeutically effective amount of a  
2 compound as defined in claim 1 or 2 together with pharmaceutically acceptable  
3 carriers, excipients or diluents.

4. A method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of a compound having the structure of Formula I,



or its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein:

$R_1$  and  $R_2$  are independently selected from  $C_1$ - $C_6$  alkyl,  $C_3$ - $C_7$  cycloalkyl,  $C_3$ - $C_7$  cycloalkenyl or optionally substituted phenyl wherein optional substituent(s) is/are selected from  $C_1$ - $C_3$  alkyl,  $C_1$ - $C_3$  alkoxy or halogen;

$R_3$  represents  $C_1$ - $C_6$  alkyl wherein 1-3 hydrogen atom(s) may be replaced by  $C_5$ - $C_7$  cycloalkyl, 1, 3-dioxo-1, 3-dihydro-isoindolyl or optionally substituted phenyl wherein the optional substituent is/are selected from  $C_1$ - $C_4$  alkyl or halogen;


Z represents oxygen or  $NR_4$  wherein  $R_4$  represents hydrogen or  $C_1$ - $C_3$  alkyl.

5. The method according to claim 4 wherein the disease or disorder is urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesis.

6. The method for treatment or prophylaxis of an animal or a human suffering from a disease or disorder of the respiratory, urinary and gastrointestinal systems, wherein the disease or disorder is mediated through muscarinic receptors, comprising administering to said animal or human, a therapeutically effective amount of the pharmaceutical composition according to claim 3.

7. The method according to claim 6 wherein the disease or disorder urinary incontinence, lower urinary tract symptoms (LUTS), bronchial asthma, chronic obstructive pulmonary disorders (COPD), pulmonary fibrosis, irritable bowel syndrome, obesity, diabetes or gastrointestinal hyperkinesia.

8. A process of preparing a compound of Formula VI,



Formula VI (Formula I, Z=NR<sub>4</sub>)


and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites, wherein

R<sub>1</sub> and R<sub>2</sub> are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkenyl or optionally substituted phenyl wherein optional substituent(s) is/are selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen;


R<sub>3</sub> represents C<sub>1</sub>-C<sub>6</sub> alkyl wherein 1-3 hydrogen atom(s) may be replaced by C<sub>5</sub>-C<sub>7</sub> cycloalkyl, 1, 3-dioxo-1, 3-dihydro-isoindolyl or optionally substituted phenyl wherein the optional substituent is/are selected from C<sub>1</sub>-C<sub>4</sub> alkyl or halogen;

R<sub>4</sub> represents hydrogen or C<sub>1</sub>-C<sub>3</sub> alkyl, comprising

(a) condensing a compound of Formula II with a compound of Formula III




Formula II




Formula III

to give a protected compound of Formula IV wherein  $R_1$ ,  $R_2$  and  $R_4$  are the same as defined earlier and P is a protecting group for an amino group



(b) deprotecting the compound of Formula IV in the presence of a deprotecting agent to give an unprotected intermediate of Formula V wherein  $R_1$ ,  $R_2$  and  $R_4$  are the same as defined earlier,



(c) the intermediate of Formula V is N-alkylated or benzylated with a suitable alkylating or benzylating agent,  $L-R_3$  wherein L is any leaving group and  $R_3$  is the same as defined earlier, to give a compound of Formula VI wherein  $R_1$ ,  $R_2$ ,  $R_3$  and  $R_4$  are the same as defined earlier.


9. The process according to claim 8 wherein P is any protecting group for an amino group and is selected from benzyl and t-butyloxy carbonyl groups.

10. The process according to claim 8 wherein the reaction of a compound of Formula II with a compound of Formula III to give a compound of Formula IV is carried out in the presence of N-methylmorpholine and 1-hydroxybenzotriazole and a condensing agent selected from 1-(3-dimethyl amino propyl)-3-ethyl carbodiimide hydrochloride (EDC), 1,8-diazabicyclo [5.4.0]undec-7-ene (DBU) or 1,3-dicyclohexylcarbodiimide (DCC).



- 1 11. The process according to claim 8 wherein the reaction of a compound of Formula  
2 II with a compound of Formula III to give a compound of Formula IV is carried  
3 out in a solvent selected from dimethylformamide, dimethyl sulfoxide, toluene,  
4 xylene or chloroform.
- 1 12. The process according to claim 8 wherein the reaction of compound of Formula II  
2 with a compound of Formula III is carried out at 0-140°C.
- 1 13. The process according to claim 8 wherein the deprotection of a compound of  
2 Formula IV to give a compound of Formula V is carried out with a deprotecting  
3 agent selected from palladium on carbon and hydrogen, ammonium formate and  
4 palladium on carbon, trifluoroacetic acid (TFA) or hydrochloric acid.
- 1 14. The process according to claim 8 wherein the deprotection of a compound of  
2 Formula IV to give a compound of Formula V is carried out in a suitable organic  
3 solvent selected from methanol, ethanol, tetrahydrofuran or acetonitrile.
- 1 15. The process according to claim 8 wherein the N-alkylation or benzylation of a  
2 compound of Formula V to give a compound of Formula VI is carried out with an  
3 alkylating or benzylating agent, L-R<sub>3</sub> wherein L is any leaving group and R<sub>3</sub> is the  
4 same as defined earlier.
- 1 16. The process according to claim 15 wherein the leaving group is selected from  
2 halogen, O-mestyl or O-tosyl groups.
- 1 17. The process according to claim 15 wherein the N-alkylation or benzylation of a  
2 compound of Formula V to give a compound of Formula VI is carried out in the  
3 optional presence of potassium carbonate and potassium iodide in an organic  
4 solvent selected from dimethylformamide, dimethylsulfoxide, tetrahydrofuran or  
5 acetonitrile.

1 18. A process of preparing a compound of Formula X,





Formula X (Formula I, Z=O)

5 and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates,  
6 esters, enantiomers, diastereomers, N-oxides, polymorphs, prodrugs or metabolites,  
7 wherein


8 R<sub>1</sub> and R<sub>2</sub> are independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>7</sub> cycloalkyl, C<sub>3</sub>-C<sub>7</sub>  
9 cycloalkenyl or optionally substituted phenyl wherein optional substituent(s) is/are  
10 selected from C<sub>1</sub>-C<sub>3</sub> alkyl, C<sub>1</sub>-C<sub>3</sub> alkoxy or halogen; and

11 R<sub>3</sub> represents C<sub>1</sub>-C<sub>6</sub> alkyl wherein 1-3 hydrogen atom(s) may be replaced by C<sub>5</sub>-C<sub>7</sub>  
12 cycloalkyl, 1, 3-dioxo-1, 3-dihydro-isoindolyl or optionally substituted phenyl  
13 wherein the optional substituent is/are selected from C<sub>1</sub>-C<sub>4</sub> alkyl or halogen,  
14 comprising


15 (a) condensing a compound of Formula II with a compound of Formula VII



22 wherein R' is protecting group for hydroxy group, to give a protected compound of  
23 Formula VIII wherein R<sub>1</sub> and R<sub>2</sub> are the same as defined earlier and P is a  
24 protecting group for an amino group,



(b) deprotecting the compound of Formula VIII in the presence of a deprotecting agent to give an unprotected intermediate of Formula IX wherein  $R_1$  and  $R_2$  are the same as defined earlier,



(c) the intermediate of Formula IX is N-alkylated or benzylated with a suitable alkylating or benzylating agent  $L-R_3$ , wherein L is leaving group, to give a compound of Formula X wherein  $R_1$ ,  $R_2$  and  $R_3$  are the same as defined earlier.

19. The process according to claim 18 wherein P is any protecting group for an amino group selected from benzyl and t-butyloxy carbonyl groups.

20. The process according to claim 18 wherein  $R'$  is any protecting group for a hydroxy group selected from p-toluene sulfonyl or methane sulfonyl groups.

21. The process according to claim 18 wherein the reaction of a compound of Formula II with a compound of Formula VII to give a compound of Formula VIII is carried out in the presence of a condensing agent selected from 1,8-diazabicyclo[5.4.0]undecan-7-ene (DBU) or 1,4-diazabicyclo[2.2.2]octane (DABCO).

22. The process according to claim 18 wherein the reaction of a compound of Formula II with a compound of Formula VII to give a compound of Formula VIII is carried out in a solvent selected from benzene, toluene or xylene.

23. The process according to claim 18 wherein the reaction of compound of Formula II with a compound of Formula VII is carried out at 0-140°C.

24. The process according to claim 18 wherein the deprotection of a compound of Formula VIII to give a compound of Formula IX is carried out with a deprotecting agent selected from palladium on carbon and hydrogen gas and ammonium formate and palladium on carbon.

- 1 25. The process according to claim 18 wherein the deprotection of a compound of  
2 Formula VIII to give a compound of Formula IX is carried out in a suitable organic  
3 solvent selected from methanol or ethanol.
- 1 26. The process according to claim 18 wherein the N-alkylation or benzylation of a  
2 compound of Formula IX to give a compound of Formula X is carried out with a  
3 suitable alkylating or benzylating agent, L-R<sub>3</sub> wherein L is any leaving group and  
4 R<sub>3</sub> is the same as defined earlier.
- 1 27. The process according to claim 25 wherein the leaving group selected from  
2 halogen, O-mestyl or O-tosyl groups.
- 1 28. The process according to claim 25 wherein the N-alkylation or benzylation of a  
2 compound of Formula IX to give a compound of Formula X is carried out in an  
3 organic solvent selected from dimethylformamide, dimethylsulfoxide,  
4 tetrahydrofuran or acetonitrile.